Ziopharm and TriArm Therapeutics to co-develop CAR T therapies in Asia
Ziopharm and TriArm Therapeutics will launch Eden BioCell to lead clinical development and commercialization of Sleeping Beauty-generated CAR-T therapies in the People's Republic of China - including Macau and Hong Kong -, Taiwan and Korea. TriArm is a cell therapy company with operations in Germany, China and the United States that was formed by Panacea Venture Healthcare, a fund co-founded and managed by James Huang, Managing Partner of Kleiner Perkins Caufield & Byers China. For China, Taiwan and Korea, Ziopharm will license the rights to Eden BioCell for third-generation Sleeping Beauty-generated CAR-T therapies targeting the CD19 antigen. Eden BioCell will be owned 50-50 by Ziopharm and TriArm. TriArm has committed up to $35M to this joint venture. Ziopharm CEO Laurence Cooper and Panacea Venture Healthcare Managing Director James Huang will serve on Eden BioCell's Board of Directors and each party will share decision-making authority. TriArm will manage all clinical development to execute trials in China for Eden BioCell.